Furthermore, as previously mentioned, alterations in GH/IGF1 axis have been associated with increased PCa aggressiveness, wherein targeting of this axis (e.g. using IGF-IR targeted therapies) showed promising anti-tumor effects [159, 160]. The gene discussed is GH1; the disease is posterior cortical atrophy.